NCT05034536View on ClinicalTrials.gov

PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma

PHASE2RecruitingINTERVENTIONAL

Enrollment

36

Participants

Timeline

Start Date

February 7, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

December 31, 2027

Conditions

Metastatic Melanoma

Interventions

DRUG

Pembrolizumab

Intravenous infusion

DRUG

Infliximab

Intravenous infusion

DRUG

Placebo

Intravenous infusion

DRUG

Relatlimab

Intravenous infusion

DRUG

Nivolumab

Intravenous infusion

Trial Locations (1)

02114

RECRUITING

Massachusetts General Hospital Cancer Center, Boston

All Listed Sponsors

collaborator

Massachusetts Institute of Technology

OTHER

lead

Massachusetts General Hospital

OTHER